FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to the treatment of diseases of the central nervous system. Oral pharmaceutical composition for preventing or treating diseases of the central nervous system contains 5–35 wt.% particles of carbamate compound of following formula 2:
[Formula 2]
or a pharmaceutically acceptable salt, solvate or hydrate thereof as an active ingredient; 55–90 wt.% diluent; 2–6 wt.% baking powder; 0.1–4 wt.% sliding substance, where the particle diameter d(0.9) of the active ingredient particles is less than 300 mcm. Also disclosed is a method of producing an oral pharmaceutical composition.
EFFECT: group of inventions provides a stable rate of dissolution of the composition.
13 cl, 1 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MIXTURE CONTAINING CARBAMATE COMPOUND FOR PREVENTION, RELIEF OR TREATMENT OF SCHIZOPHRENIA | 2018 |
|
RU2772465C2 |
| CARBAMATE COMPOUND AND THE USE OF A COMPOSITION CONTAINING IT FOR THE PREVENTION, RELIEF OR TREATMENT OF ACUTE STRESS DISORDER OR POST-TRAUMATIC STRESS DISORDER | 2019 |
|
RU2796295C2 |
| COMPOSITIONS AND METHODS FOR TREATING CANCER | 2017 |
|
RU2770081C2 |
| PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN LOBEGLITAZONE FOR ORAL ADMINISTRATION | 2015 |
|
RU2709526C2 |
| USE OF CARBAMATE COMPOUND FOR PREVENTION, RELIEF OR TREATMENT OF TREMORS OR TREMOR SYNDROME | 2017 |
|
RU2776368C2 |
| CRYSTALLINE FORMS AND METHODS FOR OBTAINING LENVATINIB BESYLATE | 2019 |
|
RU2801812C2 |
| TABLET AND METHOD OF ITS PREPARATION | 2019 |
|
RU2796301C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
| LENALIDOMIDE TABLET COMPOSITION FOR ORAL ADMINISTRATION | 2017 |
|
RU2725074C1 |
